News Release
Merial Introduces New Molecular Technology to PUREVAX® Recombinant FeLV Vaccine to Provide Improved Potency

January 15, 2012 

Only non-adjuvanted feline leukemia vaccine to be available in convenient subcutaneous injectable

Duluth, Ga. — Today at the North American Veterinary Conference (NAVC) in Orlando, Fla., Merial announced PUREVAX® Recombinant FeLV - the newest addition to the only non-adjuvanted line of feline vaccines in the U.S. Delivered subcutaneously, PUREVAX features improved potency, and has a lower antigen concentration than the previous PUREVAX Recombinant Leukemia Vaccine.1 It will be available in early spring 2012. 

Feline leukemia virus (FeLV), while a contagious, lethal and incurable disease, is easily preventable through vaccination.2 FeLV causes cancer in about 20 percent of infected cats3 and contributes to other infectious diseases and anemia by suppressing the immune system and function of bone marrow.4 The American Association of Feline Practitioners (AAFP) recommends FeLV vaccination for all kittens,5 and an annual booster inoculation is recommended in cats considered to be at risk of exposure - namely those not housed strictly indoors.5

"PUREVAX Recombinant FeLV offers the convenience of subcutaneous delivery with the efficacy and safety you would expect from a non-adjuvanted recombinant vaccine," said Dr. Robert Menardi, marketing director for Pet Vaccines, Merial. "Non-adjuvanted vaccines may help reduce the potential risk of reactions caused by unnecessary proteins and adjuvants,6 including injection site reaction,7 injection site granuloma7 or chronic inflammation."7



®PUREVAX is a registered trademark of Merial. ©2012 Merial Limited, Duluth, GA. All rights reserved.

1Merial Data on File.
2Feline Leukemia Virus and Related Diseases (Feline lymphoma and leukemia, Lymphosarcoma). In: Kahn CM, ed. The Merck Veterinary Manual. 10th ed. Whitehouse Station, NJ: Merck & Co., Inc; 2010: 718-722.
3Schaer M. Clinical Medicine of the Dog and Cat. London: Mansom Publishing; 2003: 100.
4Hartmann K. Chapter 13 - Feline Leukemia Virus Infection. In: Greene CE, ed. Infectious Diseases of the Dog and Cat. 3rd ed. Philadelphia: WB Saunders Co., 2006: 105-131.
5Richards JR, et al. The 2006 American Association of Feline Practitioners Feline Vaccine Advisory Panel Report. JAVMA 2006; 229(9); 1405-1441.
6Macy DW, Hendrick MJ. The potential role of inflammation in the development of post vaccinal sarcoma in cats. Vet Clin North Am Small Animal Pract. 1996;26(1): 103-108.
7Macy DW. The Potential Role and Mechanisms of FELV Vaccine-Induced Neoplasms. Seminars in Vet Medicine and Surgery (Small Animal) 1995; 10(4):234-237
8El Garch HE, Richard S, Piras F, et al: Feline Leukemia Virus (FeLV)-specific IFNY+T-cell responses are induced in cats following transdermal vaccination with a recombinant FeLV vaccine. Intern J Appl Res Vet Med. 2006;4(2);100-108
9Grosenbaugh DA, Leard T, Pardo MC. Protection from challenge following administration of a canarypox virus-vectored recombinant feline leukemia virus vaccine in cats previously vaccinated with a killed virus vaccine. JAVMA. 2006;228(5);726-727
10Poulet H, Brunet S, Boularand C, et al. Efficacy of a canarypox virus-vectored vaccine against feline leukaemia. Vet Rec. 2003;153(3);141-145

For further information please contact:

Natasha Mahanes


Merial developed PUREVAX Recombinant FeLV in response to customer desire for a safe, efficacious, non-adjuvanted product with convenient delivery. PUREVAX Recombinant FeLV uses recombinant canarypox-vectored vaccine technology, which stimulates FeLV-specific cell-mediated immunity8 and is proven effective in the face of severe challenge.9,10

PUREVAX Recombinant FeLV is recommended for the vaccination of healthy cats 8 weeks or older as an aid in the prevention of disease due to feline leukemia virus. For primary vaccination, cats should receive two 1-ml dose vaccinations, three weeks apart. Annual booster injections are recommended in cats considered to be at risk of exposure. Diagnostic testing for FeLV prior to vaccination also is recommended.

About Merial
Merial is a world-leading, innovation-driven animal health company, providing a comprehensive range of products to enhance the health, well-being and performance of a wide range of animals. Merial employs approximately 5,600 people and operates in more than 150 countries worldwide. Its 2010 sales were more than $2.6 billion.

Merial is a Sanofi company.

Print                   Close Window